sm 1 peptide has been researched along with Colitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Gong, F; Gu, Y; Guo, W; Shao, F; Sun, J; Sun, Y; Tan, T; Tan, Y; Wu, X; Xu, Q; Zheng, B | 1 |
| Fei, MJ; Shu, RG; Tan, RX; Wu, XF; Xu, Q | 1 |
2 other study(ies) available for sm 1 peptide and Colitis
| Article | Year |
|---|---|
A fumigaclavine C isostere alleviates Th1-mediated experimental colitis via competing with IFN-γ for binding to IFN-γ receptor 1.
Topics: Animals; Cell Differentiation; Colitis; Ergot Alkaloids; Indole Alkaloids; Interferon gamma Receptor; Interferon-gamma; Mice; Mice, Inbred C57BL; Receptors, Interferon; Signal Transduction; STAT1 Transcription Factor; Th1 Cells | 2017 |
Fumigaclavine C, an fungal metabolite, improves experimental colitis in mice via downregulating Th1 cytokine production and matrix metalloproteinase activity.
Topics: Acremonium; Animals; Colitis; Colon; Cytokines; Disease Models, Animal; Ergot Alkaloids; Female; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Indole Alkaloids; Inflammation; Lymph Nodes; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Th1 Cells; Trinitrobenzenesulfonic Acid | 2005 |